Inhibition of IL-6–Induced Apoptosis of 1A9-M Cells by a Dominant-Negative Form of Stat3 and by Constitutively Expressed BCL2
| Transfectant . | Increase of Subdiploid (%) . | Loss of Viability (%) . |
|---|---|---|
| Parent 1A9-M | 32.4 ± 1.52 | 33.0 ± 3.40 |
| 1A9-M/pCAGGS clone 1 | 30.7 ± 1.77 | 39.7 ± 5.35 |
| 1A9-M/pCAGGS clone 2 | 32.4 ± 1.71 | 41.3 ± 3.68 |
| 1A9-M/pCAGGS clone 3 | 29.9 ± 2.32 | 38.4 ± 3.69 |
| 1A9-M/ST3D clone 1 | 0.8 ± 0.29 | 3.7 ± 1.41 |
| 1A9-M/ST3D clone 2 | 0.7 ± 0.25 | 3.3 ± 0.94 |
| 1A9-M/ST3D clone A | 4.9 ± 1.22 | 7.7 ± 1.25 |
| 1A9-M/ST3D clone B | 33.5 ± 1.57 | 42.4 ± 2.87 |
| 1A9-M/BCL2 clone 1 | 0.2 ± 0.29 | 3.0 ± 1.41 |
| 1A9-M/BCL2 clone 2 | 1.3 ± 0.43 | 4.4 ± 1.25 |
| 1A9-M/BCL2 clone 3 | 3.3 ± 0.71 | 7.7 ± 2.05 |
| Transfectant . | Increase of Subdiploid (%) . | Loss of Viability (%) . |
|---|---|---|
| Parent 1A9-M | 32.4 ± 1.52 | 33.0 ± 3.40 |
| 1A9-M/pCAGGS clone 1 | 30.7 ± 1.77 | 39.7 ± 5.35 |
| 1A9-M/pCAGGS clone 2 | 32.4 ± 1.71 | 41.3 ± 3.68 |
| 1A9-M/pCAGGS clone 3 | 29.9 ± 2.32 | 38.4 ± 3.69 |
| 1A9-M/ST3D clone 1 | 0.8 ± 0.29 | 3.7 ± 1.41 |
| 1A9-M/ST3D clone 2 | 0.7 ± 0.25 | 3.3 ± 0.94 |
| 1A9-M/ST3D clone A | 4.9 ± 1.22 | 7.7 ± 1.25 |
| 1A9-M/ST3D clone B | 33.5 ± 1.57 | 42.4 ± 2.87 |
| 1A9-M/BCL2 clone 1 | 0.2 ± 0.29 | 3.0 ± 1.41 |
| 1A9-M/BCL2 clone 2 | 1.3 ± 0.43 | 4.4 ± 1.25 |
| 1A9-M/BCL2 clone 3 | 3.3 ± 0.71 | 7.7 ± 2.05 |
1A9-M/pCAGGS (clone 1-3), 1A9-M/ST3D (clone 1, 2, A, B), 1A9-M/BCL2 (clone 1-3), and parent 1A9-M cells were cultured with or without 20 ng/mL IL-6 for 48 hours. Nuclear DNA content was analyzed with FACSort using Cell Quest software. Cell viability was determined by trypan blue dye exclusion. The increase of subdiploid or dead cell populations by IL-6 treatment is shown as the mean ± SD of triplicate cultures.